The Role of Il-12 and type I Interferon in governing the magnitude of CD8 T cell responses

Advances in Experimental Medicine and Biology

Volumn 850, Issue , 2015, Pages 31-41

  Starbeck Miller, Gabriel R ^a   Harty, John T ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

CD8 T cells; Inflammatory cytokines; Interleukin 12; Interleukin 2; Signal 3; Type I interferon

Indexed keywords

INTERFERON; INTERLEUKIN 12; ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; ARTICLE; BINDING AFFINITY; BIOACCUMULATION; CD8+ T LYMPHOCYTE; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR IMMUNITY; CYTOKINE RELEASE; ENZYME ACTIVATION; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; B LYMPHOCYTE; COMMUNICABLE DISEASE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; COMMUNICABLE DISEASES; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERFERON-ALPHA; INTERFERON-BETA; INTERFERON-GAMMA; INTERLEUKIN-12; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84940878343     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-15774-0_3     Document Type: Article

References (55)

1. Acuto, O., & Michel, F. (2003). CD28-mediated co-stimulation: A quantitative support for TCR signalling. Nature Reviews Immunology, 3, 939-951.
2. Aichele, P., Unsoeld, H., Koschella, M., Schweier, O., Kalinke, U., & Vucikuja, S. (2006). CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion. Journal of Immunology, 176, 4525-4529.
3. Badovinac, V. P., & Harty, J. T. (2006). Programming, demarcating, and manipulating CD8+ T-cell memory. Immunological Reviews, 211, 67-80.
4. Besser, M. J., Shapira-Frommer, R., Treves, A. J., Zippel, D., Itzhaki, O., Hershkovitz, L., Levy, D., Kubi, A., Hovav, E., Chermoshniuk, N., Shalmon, B., Hardan, I., Catane, R., Markel, G., Apter, S., Ben-Nun, A., Kuchuk, I., Shimoni, A., Nagler, A., & Schachter, J. (2010). Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clinical Cancer Research, 16, 2646-2655.
5. Bevan, M. J. (1976). Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. Journal of Experimental Medicine, 143, 1283-1288.
6. Boyman, O., & Sprent, J. (2012). The role of interleukin-2 during homeostasis and activation of the immune system. Nature Reviews Immunology, 12, 180-190.
7. Crompton, J. G., Sukumar, M., & Restifo, N. P. (2014). Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. Immunological Reviews, 257, 264-276.
8. Curtsinger, J. M., Schmidt, C. S., Mondino, A., Lins, D. C., Kedl, R. M., Jenkins, M. K., & Mescher, M. F. (1999). Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. Journal of Immunology, 162, 3256-3262.
9. Curtsinger, J. M., Valenzuela, J. O., Agarwal, P., Lins, D., & Mescher, M. F. (2005). Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. Journal of Immunology, 174, 4465-4469.
10. Gately, M. K., Wolitzky, A. G., Quinn, P. M., & Chizzonite, R. (1992). Regulation of human cytolytic lymphocyte responses by interleukin-12. Cellular Immunology, 143, 127-142.
11. Gately, M. K., Warrier, R. R., Honasoge, S., Carvajal, D. M., Faherty, D. A., Connaughton, S. E., Anderson, T. D., Sarmiento, U., Hubbard, B. R., & Murphy, M. (1994). Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. International Immunology, 6, 157-167.
12. Gil, M. P., Ploquin, M. J., Watford, W. T., Lee, S. H., Kim, K., Wang, X., Kanno, Y., O'shea, J. J., & Biron, C. A. (2012). Regulating type 1 IFN effects in CD8 T cells during viral infections: Changing STAT4 and STAT1 expression for function. Blood, 120, 3718-3728.
13. Guermonprez, P., Saveanu, L., Kleijmeer, M., Davoust, J., Van Endert, P., & Amigorena, S. (2003). ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature, 425, 397-402.
14. Harty, J. T., & Badovinac, V. P. (2008). Shaping and reshaping CD8+ T-cell memory. Nature Reviews Immunology, 8, 107-119.
15. Houde, M., Bertholet, S., Gagnon, E., Brunet, S., Goyette, G., Laplante, A., Princiotta, M. F., Thibault, P., Sacks, D., & Desjardins, M. (2003). Phagosomes are competent organelles for antigen cross-presentation. Nature, 425, 402-406.
16. Joffre, O. P., Segura, E., Savina, A., & Amigorena, S. (2012). Cross-presentation by dendritic cells. Nature Reviews Immunology, 12, 557-569.
17. Kaech, S. M., Wherry, E. J., & Ahmed, R. (2002). Effector and memory T-cell differentiation: Implications for vaccine development. Nature Reviews Immunology, 2, 251-262.
18. Keppler, S. J., Theil, K., Vucikuja, S., & Aichele, P. (2009). Effector T-cell differentiation during viral and bacterial infections: Role of direct IL-12 signals for cell fate decision of CD8(+) T cells. European Journal of Immunology, 39, 1774-1783.
19. Keppler, S. J., Rosenits, K., Koegl, T., Vucikuja, S., & Aichele, P. (2012). Signal 3 cytokines as modulators of primary immune responses during infections: The interplay of type I IFN and IL-12 in CD8 T cell responses. PLoS ONE, 7, e40865.
20. Kolumam, G. A., Thomas, S., Thompson, L. J., Sprent, J., & Murali-Krishna, K. (2005). Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. Journal of Experimental Medicine, 202, 637-650.
21. Koretzky, G. A., Abtahian, F., & Silverman, M. A. (2006). SLP76 and SLP65: complex regulation of signalling in lymphocytes and beyond. Nature Reviews Immunology, 6, 67-78.
22. Ledbetter, J. A., Gentry, L. E., June, C. H., Rabinovitch, P. S., & Purchio, A. F. (1987). Stimulation of T cells through the CD3/T-cell receptor complex: Role of cytoplasmic calcium, protein kinase C translocation, and phosphorylation of pp60c-src in the activation pathway. Molecular and Cellular Biology, 7, 650-656.
23. Levin, A. M., Bates, D. L., Ring, A. M., Krieg, C., Lin, J. T., SU, L., Moraga, I., Raeber, M. E., Bowman, G. R., Novick, P., Pande, V. S., Fathman, C. G., Boyman, O., & Garcia, K. C. (2012). Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature, 484, 529-33.
24. Marrack, P., Kappler, J., & Mitchell, T. (1999). Type I interferons keep activated T cells alive. Journal of Experimental Medicine, 189, 521-530.
25. Medzhitov, R. (2001). Toll-like receptors and innate immunity. Nature Reviews Immunology, 1, 135-145.
26. Mehrotra, P. T., Wu, D., Crim, J. A., Mostowski, H. S., & Siegel, J. P. (1993). Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. Journal of Immunology, 151, 2444-2452.
27. Mescher, M. F., Curtsinger, J. M., Agarwal, P., Casey, K. A., Gerner, M., Hammerbeck, C. D., Popescu, F., & Xiao, Z. (2006). Signals required for programming effector and memory development by CD8+ T cells. Immunological Reviews, 211, 81-92.
28. Mitchell, T. C., Hildeman, D., Kedl, R. M., Teague, T. K., Schaefer, B. C., White, J., Zhu, Y., Kappler, J., & Marrack, P. (2001). Immunological adjuvants promote activated T cell survival via induction of Bcl-3. Nature Immunology, 2, 397-402.
29. Obar, J. J., Molloy, M. J., Jellison, E. R., Stoklasek, T. A., Zhang, W., Usherwood, E. J., & Lefrancois, L. (2010). CD4+ T cell regulation of CD25 expression controls development of shortlived effector CD8+ T cells in primary and secondary responses. Proceedings of the National Academy of Sciences of the United States of America, 107, 193-198.
30. Pham, N. L., Badovinac, V. P., & Harty, J. T. (2009). A default pathway of memory CD8 T cell differentiation after dendritic cell immunization is deflected by encounter with inflammatory cytokines during antigen-driven proliferation. Journal of Immunology, 183, 2337-2348.
31. Pipkin, M. E., Sacks, J. A., Cruz-Guilloty, F., Lichtenheld, M. G., Bevan, M. J., & Rao, A. (2010). Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity, 32, 79-90.
32. Radvanyi, L. G., Bernatchez, C., Zhang, M., Fox, P. S., Miller, P., Chacon, J., Wu, R., Lizee, G., Mahoney, S., Alvarado, G., Glass, M., Johnson, V. E., Mcmannis, J. D., Shpall, E., Prieto, V., Papadopoulos, N., Kim, K., Homsi, J., Bedikian, A., Hwu, W. J., Patel, S., Ross, M. I., Lee, J. E., Gershenwald, J. E., Lucci, A., Royal, R., Cormier, J. N., Davies, M. A., Mansaray, R., Fulbright, O. J., Toth, C., Ramachandran, R., Wardell, S., Gonzalez, A., & Hwu, P. (2012). Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clinical Cancer Research, 18, 6758-6770.
33. Randolph, G. J., Ochando, J., & Partida-Sanchez, S. (2008). Migration of dendritic cell subsets and their precursors. Annual Review of Immunology, 26, 293-316.
34. Renauld, J. C., Vink, A., & Van Snick, J. (1989). Accessory signals in murine cytolytic T cell responses. Dual requirement for IL-1 and IL-6. Journal of Immunology, 143, 1894-1898.
35. Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012). Adoptive immunotherapy for cancer: Harnessing the T cell response. Nature Reviews Immunology, 12, 269-281.
36. Robbins, P. F., Dudley, M. E., Wunderlich, J., El-Gamil, M., LI, Y. F., Zhou, J., Huang, J., Powell, D. J., Jr., & Rosenberg, S. A. (2004). Cutting edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. Journal of Immunology, 173, 7125-7130.
37. Rock, K. L., & Shen, L. (2005). Cross-presentation: underlying mechanisms and role in immune surveillance. Immunological Reviews, 207, 166-183.
38. Rosenberg, S. A., & Dudley, M. E. (2009). Adoptive cell therapy for the treatment of patients with metastatic melanoma. Current Opinion in Immunology, 21, 233-240.
39. Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., Morton, K. E., Laurencot, C. M., Steinberg, S. M., White, D. E., & Dudley, M. E. (2011). Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clinical Cancer Research, 17, 4550-4557.
40. Saito, T., Yokosuka, T., & Hashimoto-Tane, A. (2010). Dynamic regulation of T cell activation and co-stimulation through TCR-microclusters. FEBS Letters, 584, 4865-4871.
41. Saveanu, L., Carroll, O., Weimershaus, M., Guermonprez, P., Firat, E., Lindo, V., Greer, F., Davoust, J., Kratzer, R., Keller, S. R., Niedermann, G., & Van Endert, P. (2009). IRAP identifies an endosomal compartment required for MHC class I cross-presentation. Science, 325, 213-217.
42. Schmidt, C. S., & Mescher, M. F. (1999). Adjuvant effect of IL-12: Conversion of peptide antigen administration from tolerizing to immunizing for CD8+ T cells in vivo. Journal of Immunology, 163, 2561-2567.
43. Serwold, T., Gonzalez, F., Kim, J., Jacob, R., & Shastri, N. (2002). ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature, 419, 480-483.
44. Simon, M. M., Landolfo, S., Diamantstein, T., & Hochgeschwender, U. (1986). Antigen- and lectin- sensitized murine cytolytic T lymphocyte-precursors require both interleukin 2 and endogenously produced immune (gamma) interferon for their growth and differentiation into effector cells. Current Topics in Microbiology and Immunology, 126, 173-185.
45. Smith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009). T cell activation. Annual Review of Immunology, 27, 591-619.
46. Sommers, C. L., Samelson, L. E., & Love, P. E. (2004). LAT: A T lymphocyte adapter protein that couples the antigen receptor to downstream signaling pathways. Bioessays, 26, 61-67.
47. Starbeck-Miller, G. R., Xue, H. H., & Harty, J. T. (2014). IL-12 and type I interferon prolong the division of activated CD8 T cells by maintaining high-affinity IL-2 signaling in vivo. Journal of Experimental Medicine, 211, 105-120.
48. Trombetta, E. S., & Mellman, I. (2005). Cell biology of antigen processing in vitro and in vivo. Annual Review of Immunology, 23, 975-1028.
49. Valenzuela, J., Schmidt, C., & Mescher, M. (2002). The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells. Journal of Immunology, 169, 6842-6849.
50. Valenzuela, J. O., Hammerbeck, C. D., & Mescher, M. F. (2005). Cutting edge: Bcl-3 up-regulation by signal 3 cytokine (IL-12) prolongs survival of antigen-activated CD8 T cells. Journal of Immunology, 174, 600-604.
51. Vignali, D. A., & Kuchroo, V. K. (2012). IL-12 family cytokines: Immunological playmakers. Nature Immunology, 13, 722-728.
52. Williams, M. A., Tyznik, A. J., & Bevan, M. J. (2006). Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature, 441, 890-893.
53. Xue, L., Chiang, L., HE, B., Zhao, Y. Y., & Winoto, A. (2010). FoxM1, a forkhead transcription factor is a master cell cycle regulator for mouse mature T cells but not double positive thymocytes. PLoS ONE, 5, e9229.
54. York, I. A., Chang, S. C., Saric, T., Keys, J. A., Favreau, J. M., Goldberg, A. L., & Rock, K. L. (2002). The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nature Immunology, 3, 1177-1184.
55. Zhang, W., Sommers, C. L., Burshtyn, D. N., Stebbins, C. C., Dejarnette, J. B., Trible, R. P., Grinberg, A., Tsay, H. C., Jacobs, H. M., Kessler, C. M., Long, E. O., Love, P. E., & Samelson, L. E. (1999). Essential role of LAT in T cell development. Immunity, 10, 323-332.